{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:37:40Z","timestamp":1790689060504,"version":"4.1.0"},"reference-count":39,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T00:00:00Z","timestamp":1723420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Veterinary Dermatology"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Mycophenolate is an immunomodulating agent successfully used for the treatment of moderate\u2010to\u2010severe atopic dermatitis (AD) in people. Mycophenolate is an effective steroid\u2010sparing treatment option for use in dogs with inflammatory skin diseases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate whether once\u2010daily modified\u2010release mycophenolate (OKV\u20101001) is safe and effective for treating moderate\u2010to\u2010severe canine AD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Animals<\/jats:title><jats:p>Client\u2010owned atopic dogs (<jats:italic>n<\/jats:italic>\u2009=\u20099) were enrolled.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>In an open\u2010label multicentre pilot study, OKV\u20101001 (30\u2009mg\/kg every 24\u2009h) was given orally for \u226484\u2009days. Concomitant tapering doses of glucocorticoids were administered up to Day (D)28. Clinicians assessed Canine Atopic Dermatitis Extent and Severity Index, 4th iteration (CADESI\u201004) on D0, D14, D28, D56 and D84. Body weight and clinical pathological parameters were measured at baseline and at the end of the study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Treatment with OKV\u20101001 combined with glucocorticoids significantly reduced the severity of AD within two\u2009weeks in seven of nine (77.8%) dogs. The mean percentage change from baseline in the CADESI\u201004 score was 29% (<jats:italic>p<\/jats:italic>\u2009=\u20090.009) at D14 (<jats:italic>n<\/jats:italic>\u2009=\u20099), 39% (<jats:italic>p<\/jats:italic>\u2009=\u20090.008) at D28 (<jats:italic>n<\/jats:italic>\u2009=\u20099) and 49% (<jats:italic>p<\/jats:italic>\u2009=\u20090.03) at D56 (<jats:italic>n<\/jats:italic>\u2009=\u20097) at which point glucocorticoids had been withdrawn. In two dogs the improvement in CADESI\u201004 was 62% and 23% (respectively) on D84. No significant adverse events including clinical pathological findings were reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Clinical Relevance<\/jats:title><jats:p>Modified\u2010release mycophenolate (OKV\u20101001) may represent a promising alternative treatment option for dogs with moderate\u2010to\u2010severe AD. The safety and efficacy profile of OKV\u20101001 will need to be established in larger, placebo\u2010controlled clinical trials.<\/jats:p><\/jats:sec>","DOI":"10.1111\/vde.13283","type":"journal-article","created":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T09:25:13Z","timestamp":1723454713000},"page":"652-661","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Treatment of moderate\u2010to\u2010severe canine atopic dermatitis with modified\u2010release mycophenolate (<scp>OKV<\/scp>\u20101001): A pilot open\u2010label, single\u2010arm multicentric clinical trial"],"prefix":"10.1111","volume":"35","author":[{"given":"Michael","family":"Klotsman","sequence":"first","affiliation":[{"name":"Okava Pharmaceuticals  San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne H.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Okava Pharmaceuticals  San Francisco California USA"},{"name":"Pulmonary and Critical Care Medicine University of North Carolina at Chapel Hill  Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Wyatt","sequence":"additional","affiliation":[{"name":"Dermatology Clinic for Animals  Lacey Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Lewis","sequence":"additional","affiliation":[{"name":"Dermatology for Animals  Gilbert Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Theus","sequence":"additional","affiliation":[{"name":"MedVet Columbus  Worthington Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4893-4289","authenticated-orcid":false,"given":"Domenico","family":"Santoro","sequence":"additional","affiliation":[{"name":"Department of Small Animal Clinical Sciences, College of Veterinary Medicine University of Florida  Gainesville Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,8,12]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvp.12731"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0162-3109(00)00188-0"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12610346"},{"key":"e_1_2_9_5_1","volume-title":"CellCept [package insert]","year":"2015"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2008101028"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.124575"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.08.049"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2010.91"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14891"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08978.x"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.03.030"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2000.03667.x"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.04.027"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/vetsci8050072"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12747"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.13028"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.4102\/jsava.v81i4.157"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcam.2022.100755"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.17236\/sat00203"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12400"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/vetsci4030037"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvp.12950"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0039-8"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.3389\/fvets.2020.611404"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2009.00784.x"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cvsm.2018.08.002"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12740"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12917-015-0514-6"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2009.00758.x"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12917-015-0515-5"},{"key":"e_1_2_9_32_1","first-page":"870","article-title":"Mycophenolate mofetil is effective in the treatment of atopic dermatitis","volume":"137","author":"Grundmann\u2010Kollmann M","year":"2001","journal-title":"Arch Dermatol"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12107"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.13134"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvim.16209"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2006.10.189"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-4431.2009.00433.x"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12285"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12917-018-1569-y"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2010.00899.x"}],"container-title":["Veterinary Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vde.13283","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:32:48Z","timestamp":1743553968000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vde.13283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,12]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1111\/vde.13283"],"URL":"https:\/\/doi.org\/10.1111\/vde.13283","archive":["Portico"],"relation":{},"ISSN":["0959-4493","1365-3164"],"issn-type":[{"value":"0959-4493","type":"print"},{"value":"1365-3164","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,12]]},"assertion":[{"value":"2024-03-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}